Literature DB >> 18980856

LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay.

Ignacio F Mata1, Carlos Cosentino, Victoria Marca, Luis Torres, Pilar Mazzetti, Olimpio Ortega, Victor Raggio, Ruth Aljanati, Ricardo Buzó, Dora Yearout, Elena Dieguez, Cyrus P Zabetian.   

Abstract

Variation in the leucine-rich repeat kinase 2 (LRRK2) gene represents the most common genetic determinant of Parkinson's disease (PD) identified to date. While the frequency and distribution of LRRK2 mutations have been well-studied in Europe and North America, few data are available from South America. To address this gap in knowledge, we screened two cohorts of patients with PD from Peru (n=240) and Uruguay (n=125) for the three most common LRRK2 mutations (R1441C, R1441G, G2019S). We identified at total of seven patients with mutations, one with R1441G, and six with G2019S. The carrier frequency was significantly greater in the Uruguayan cohort (4.8%) than in the Peruvian cohort (0.4%; p=0.007). This likely resulted from a greater admixture proportion in the Peruvian sample. Haplotype analyses suggested that G2019S was probably brought to Peru and Uruguay by European settlers. In contrast, the origin of R1441G in our cohort was not clear, as the patient with this mutation had a background haplotype that was clearly distinct from that reported in carriers from Europe and North America. Our data add to a growing body of evidence indicating that LRRK2 mutations are widely distributed across South America but might differ by region in prevalence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18980856     DOI: 10.1016/j.parkreldis.2008.09.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  16 in total

1.  Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America.

Authors:  Ignacio F Mata; Greggory J Wilhoite; Dora Yearout; Justin A Bacon; Mario Cornejo-Olivas; Pilar Mazzetti; Victoria Marca; Olimpio Ortega; Oscar Acosta; Carlos Cosentino; Luis Torres; Angel C Medina; Carolina Perez-Pastene; Fernando Díaz-Grez; Carles Vilariño-Güell; Pablo Venegas; Marcelo Miranda; Osvaldo Trujillo-Godoy; Luis Layson; Rodrigo Avello; Elena Dieguez; Victor Raggio; Federico Micheli; Claudia Perandones; Victoria Alvarez; Juan Segura-Aguilar; Matthew J Farrer; Cyrus P Zabetian; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2011-05-31       Impact factor: 4.891

Review 2.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

3.  Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization.

Authors:  Rachel Saunders-Pullman; Johann Hagenah; Vijay Dhawan; Kaili Stanley; Gregory Pastores; Swati Sathe; Michele Tagliati; Kelly Condefer; Christina Palmese; Norbert Brüggemann; Christine Klein; Am Roe; Ruth Kornreich; Laurie Ozelius; Susan Bressman
Journal:  Mov Disord       Date:  2010-07-30       Impact factor: 10.338

4.  Cognitive profile of LRRK2-related Parkinson's disease.

Authors:  Sindhu Srivatsal; Brenna Cholerton; James B Leverenz; Zbigniew K Wszolek; Ryan J Uitti; Dennis W Dickson; Daniel Weintraub; John Q Trojanowski; Vivianna M Van Deerlin; Joseph F Quinn; Kathryn A Chung; Amie L Peterson; Stewart A Factor; Cathy Wood-Siverio; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Beate Ritz; Rebecca Rausch; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Ignacio F Mata; Shu-Ching Hu; Kathleen S Montine; Catherine Johnson; Thomas J Montine; Karen L Edwards; Jing Zhang; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

5.  Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain.

Authors:  Ignacio F Mata; Victoria Alvarez; Renee Ribacoba; Jon Infante; María Sierra; Pilar Gómez-Garre; Pablo Mir; Sarah Waldherr; Dora Yearout; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2013-02-06       Impact factor: 10.338

6.  Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries.

Authors:  Anat Bar-Shira; Carolyn M Hutter; Nir Giladi; Cyrus P Zabetian; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2009-03-13       Impact factor: 2.660

7.  Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson's Disease Patients.

Authors:  Andrés Felipe Duque; Juan Carlos Lopez; Bruno Benitez; Helena Hernandez; Juan José Yunis; William Fernandez; Humberto Arboleda; Gonzalo Arboleda
Journal:  Colomb Med (Cali)       Date:  2015-09-30

8.  The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.

Authors:  Ignacio F Mata; Marie Y Davis; Alexis N Lopez; Michael O Dorschner; Erica Martinez; Dora Yearout; Brenna A Cholerton; Shu-Ching Hu; Karen L Edwards; Thomas D Bird; Cyrus P Zabetian
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-04-25       Impact factor: 3.568

9.  Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.

Authors:  Taku Hatano; Manabu Funayama; Shin-Ichiro Kubo; Ignacio F Mata; Yutaka Oji; Akio Mori; Cyrus P Zabetian; Sarah M Waldherr; Hiroyo Yoshino; Genko Oyama; Yasushi Shimo; Ken-Ichi Fujimoto; Hirokazu Oshima; Yasuto Kunii; Hirooki Yabe; Yoshikuni Mizuno; Nobutaka Hattori
Journal:  Neurobiol Aging       Date:  2014-06-02       Impact factor: 4.673

10.  Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan.

Authors:  Yuanzhe Li; Aya Ikeda; Hiroyo Yoshino; Genko Oyama; Mitsuhiro Kitani; Kensuke Daida; Arisa Hayashida; Kotaro Ogaki; Kousuke Yoshida; Takashi Kimura; Yoshiaki Nakayama; Hidefumi Ito; Naoto Sugeno; Masashi Aoki; Hiroaki Miyajima; Katsuo Kimura; Naohisa Ueda; Masao Watanabe; Takao Urabe; Masashi Takanashi; Manabu Funayama; Kenya Nishioka; Nobutaka Hattori
Journal:  J Hum Genet       Date:  2020-05-13       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.